China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm Sinopharm Group to jointly advance the marketing and commercialization of Neurophth’s NFS-01, an ophthalmic gene therapy targeting ND4 mutation in Leber’s Hereditary Optic Neuropathy (LHON) disease. Neurophth is aiming for NFS-01 to achieve a first-of-its-kind market approval in China, potentially as early as 2025. Additionally, Neurophth’s NFS-02, which targets the ND1 mutation in LHON disease, is undergoing clinical studies in both China and the US.
Collaboration Focus and Scope
Neurophth and Sinopharm will collaborate on a range of activities, including pre-market approval distribution and logistics management, post-market commercial storage and distribution, direct-to-patient (DTP) pharmacy services, and innovative payment solutions. This partnership leverages Sinopharm’s extensive network and experience in pharmaceutical distribution and marketing, complementing Neurophth’s expertise in gene therapy development.
Financial Details and Potential Impact
While no financial details of the partnership have been disclosed, the collaboration is expected to significantly impact the accessibility and affordability of gene therapy treatments for LHON disease in China. The partnership aims to streamline the process from clinical trials to patient access, ensuring that innovative therapies like NFS-01 and NFS-02 can reach those in need.-Fineline Info & Tech
